Empagliflozin
Approved · EMAAlso known as 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene, Glyxambi, Jardiance, Synjardy+4 more
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene, Glyxambi, Jardiance, Synjardy, Trijardy, Empagliflozina, Empagliflozine, Empagliflozinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Empagliflozin improves HbA1c in type 2 diabetes — High confidence reached
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
Confidence is high because multiple independent trials consistently report HbA1c, with a narrow uncertainty band; publication incorporation remains limited.
High point estimate, but substantial uncertainty remains.
Confidence has a low point estimate but a wide uncertainty band — the evidence is still sponsor-concentrated.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an… Show full indicationShow less
Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney disease Jardiance is indicated in adults for the treatment of chronic kidney disease.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
SAVE-Care (SGLT2i As Novel Gout Care) Trial
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Recent completions
Trials that read out recently, adding to the completed evidence base.
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine3
- Alzheimer's research & therapy1
- Circulation1
- European journal of heart failure1
- Journal of the American College of Cardiology1
- Journal of the American Heart Association1
- Brueckmann M3
- Ponikowski P3
- Anker SD2
- Bocchi E2
- Böhm M2
- Broedl UC2
- Brunner-La Rocca HP2
- Butler J2
- School of Medicine2
- 2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital Medical School National and Kapodistrian University of Athens Athens Greece.1
- 2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital Medical School National and Kapodistrian University of Athens Athens Greece.1
- Akershus University Hospital1
- Beijing Anzhen Hospital1
- Cardiovascular Institute1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 7 of the same disease areas as Empagliflozin in the shared literature.
Studied across 6 of the same disease areas as Empagliflozin in the shared literature.
Studied across 3 of the same disease areas as Empagliflozin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.